Palisade Bio
PALI · NASDAQ
$1.43+$0.09 (+6.72%)TodayMarket closed ·
Prev close $1.34
EPS: actual vs estimate
Beat the estimate in 5 of the last 8 quarters, by 19.9% on average
Reported EPS
Estimated EPS
| Quarter | Estimate | Reported | Surprise |
|---|---|---|---|
| Q2 FY26 | -$0.0533 | -$0.05 | +6.2% |
| Q1 FY26 | -$0.0437 | -$0.05 | −14.4% |
| Q4 FY25 | -$0.0829 | -$0.08 | +3.5% |
| Q3 FY25 | -$0.2798 | -$0.38 | −35.8% |
| Q2 FY25 | -$0.5719 | -$0.58 | −1.4% |
| Q1 FY25 | -$0.714 | -$0.47 | +34.2% |
| Q4 FY24 | -$2.03 | -$1.55 | +23.7% |
| Q3 FY24 | -$3.42 | -$2.32 | +32.2% |
Earnings calls
- Morgan Stanley 24th Annual Global Healthcare Conference
- Special Call - Palisade Bio, Inc.
- Leading BioSciences, Inc., Seneca Biopharma, Inc. - M&A Call
- Leading BioSciences Inc, Seneca Biopharma, Inc. - M&A Call
- Neuralstem: Wall Street Analyst Forum Presentation Transcript
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.